Trying to learn how to translate from the human translation examples.
From: Machine Translation
Suggest a better translation
Quality:
From professional translators, enterprises, web pages and freely available translation repositories.
non-squamous nsclc
cpcnp de histologia não-escamosa
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
advanced non-squamous nsclc
nsclc não escamoso avançado
Last Update: 2016-05-07
Usage Frequency: 1
Quality:
Reference:
nsclc - non-small cell lng can
cancro pulmonar de células não-pequenas ne
Last Update: 2014-12-09
Usage Frequency: 1
Quality:
Reference:
Warning: This alignment may be wrong.
Please delete it you feel so.
nsclc - non-small cell lung cancer
cancro pulmonar de células não-pequenas
Last Update: 2014-12-09
Usage Frequency: 6
Quality:
Reference:
Warning: This alignment may be wrong.
Please delete it you feel so.
use of nivolumab in non-squamous nsclc
uso de nivolumab no cpcnp de histologia não escamosa
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
studies have shown benefit in two forms of nsclc, known as non-squamous and squamous.
os estudos demonstraram benefícios em duas formas de cpcnp (escamoso e não escamoso).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
first-line treatment of non-squamous nsclc in combination with platinum-based chemotherapy
tratamento de primeira linha de nsclc não escamoso em associação com quimioterapia baseada em platina
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
improved survival times with alimta were only seen in patients with non small cell lung cancer of the non-squamous type.
as melhorias nos tempos de sobrevivência com o alimta foram observadas apenas nos doentes com cancro do pulmão de células não-pequenas do tipo não escamoso.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
for non-squamous nsclc, one main study involved 582 patients whose disease had progressed despite previous treatments.
no cpcnp não escamoso, um estudo principal incluiu 582 doentes cuja doença se agravou apesar dos tratamentos anteriores.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
in non-squamous nsclc, a higher number of deaths within 3 months was observed in nivolumab compared to docetaxel.
no cpcnp de histologia não- escamosa, foi observado, num período de 3 meses, um maior número de mortes com nivolumab quando comparado com docetaxel.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
randomization was stratified according to eastern cooperative oncology group (ecog) status (0 versus 1), bevacizumab pretreatment (yes versus no), brain metastasis (yes versus no) and tumour histology (squamous versus non-squamous tumour histology).
a aleatorização foi estratificada de acordo com o estado ecog ( eastern cooperative oncology group) (0 versus 1), pré-tratamento com bevacizumab (sim versus não), metástases cerebrais (sim versus não) e histologia tumoral (histologia tumoral escamosa versus não escamosa).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
in a clinical trial in advanced non-squamous nsclc, patients experienced an increased rate of serious thromboembolic events (including fatal events) in the necitumumab plus pemetrexed and cisplatin arm as compared to the pemetrexed and cisplatin arm (see also section 4.8).
num ensaio clínico de cpnpc avançado de histologia não-escamosa, verificou-se uma taxa mais elevada de acontecimentos tromboembólicos graves (incluindo acontecimentos fatais) nos doentes do braço de necitumumab em associação com pemetrexedo e cisplatina em comparação com os doentes do braço de pemetrexedo e cisplatina (ver também secção 4.8).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
there was no difference in orr between the treatment arms in patients with non-squamous histology (n=602, 26% vs 25%, p=0.808).
não houve qualquer diferença na orr entre os braços de tratamento nos doentes com histologia não escamosa (n=602, 26% vs 25%, p=0,808).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
the safety and efficacy of nivolumab 3 mg/kg as a single agent for the treatment of advanced or metastatic non-squamous nsclc were evaluated in a phase 3, randomised, open-label study (ca209057).
a segurança e a eficácia de nivolumab 3 mg/kg, como agente individual, para o tratamento de cpcnp de histologia não-escamosa metastático ou em estadio avançado, foram avaliadas num estudo aleatorizado, de fase 3, sem ocultação (ca209057).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
baseline patient demographics and disease characteristics were generally balanced between arms: the median age was 62 years; 67% of patients were male; 82% were caucasian, 13% asian; the ecog ps was 0 for 32% of patients, 1 for 67% of patients; 73% of patients had non-squamous histology and 26% had squamous histology.
as características demográficas e da doença na linha de base estavam, em geral, equilibradas entre os braços de tratamento: a mediana das idades era de 62 anos; 67% dos doentes eram do sexo masculino; 82% eram caucasianos e 13% asiáticos; o ecog ps era de 0 em 32% dos doentes e 1 em 67% dos doentes; 73% dos doentes tinham histologia não escamosa e 26% tinham histologia escamosa.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference: